Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/005—Antimicrobial preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers
  • A61K2800/524—Preservatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/59—Mixtures

Definitions

• Preservatives are used in personal care products (products applied to the skin or scalp either to remain there or to be rinsed off to preserve these products against microbial spoilage and to extend their shelf life.
• Antimicrobial compounds used for product preservation may fall into one or more of the following classes based on the effect they have on the microorganism, in particular bacteria and fungi.
• a germistatic compound inhibits the growth of germs, while a germicidal compound kills germs.
• An antibacterial or antifungal may inhibit growth of the microorganisms or kill them or both.
• Many antimicrobial compounds are not effective against fungal spores.
• a bacteriostatic compound inhibits growth of bacteria, while a bactericide kills bacteria (reduces their number).
• a fungistatic compound inhibits the growth of fungi (molds and yeast), while a fungicide kills fungi (reduces their number).
• a sporicide kills spores of fungi or bacteria. Spores, especially endospores, are formed by some bacteria to survive during periods of deprivation and are significantly more difficult to kill. Fungi form spores for reproduction and these spores are significantly more difficult to kill than the vegetative form of the fungi.
• a broad band preservative effect including a bactericidal and fungicidal activity was previously only partially attained in personal care products, or attained only by addition of certain fungicides, in particular formaldehyde, formaldehyde donors, halogenated compounds, compounds belonging to the class of parabens and a variety of specific fungicides.
• Formaldehyde donors include in particular diazolidinyl urea (CAS 78491-02-8), imidazolidinyl urea (CAS 39236-46-9), and DMDM Hydantoin (CAS 6440-58-0).
• Halogenated compounds include in particular 2,4-dichlorobenzyl-alcohol (CAS 1777-82-8), Chloroxylenol (also known as 4-chloro-3,5-dimethyl-phenol, CAS 88-04-0), Bronopol (also known as 2-bromo-2-nitropropane-1,3-diol, CAS 52-51-7), iodopropynyl butyl carbamate (CAS 55406-53-6).
• Chloroxylenol also known as 4-chloro-3,5-dimethyl-phenol, CAS 88-04-0
• Bronopol also known as 2-bromo-2-nitropropane-1,3-diol, CAS 52-51-7
• iodopropynyl butyl carbamate CAS 55406-53-6.
• Paraben compounds include in particular Methyl-paraben (CAS 99-76-3), Ethyl-paraben (CAS 120-47-8), Propyl-paraben (CAS 94-13-3), Butyl-paraben (CAS 94-26-8), Isopropyl-paraben (CAS 4191-73-5), and Benzyl-paraben (CAS 94-18-8).
• fungizides include Quaternium-15 (CAS 51229-78-8), methyl-chloroisothiazolinone (CAS 26172-55-4), and methylisothiazolinone (CAS 2682-20-4).
• fungicide compounds may constitute health hazards, for example, iodopropynyl butyl carbamate, formaldehyde and formaldehyde donors, methyl-chloroisothiazolinone (CAS 26172-55-4), and methylisothiazolinone are considered highly allergenic/sensitizing.
• JP2005053922 and JP2000143453 disclose hair cosmetics including shampoos that contain a large amount of phenoxyethanol.
• the comparatively large quantity of phenoxyethanol and its associated unpleasant smell is alleviated somewhat by the combination with benzaldehyde, which also has a very intensive smell which can be undesirable at higher concentrations in many personal care products.
• n is selected from 2 and 3, and when X is C, then n is selected from 0, 1, and 2.
• Formula I therefore encompasses compounds selected from the group consisting of phenoxyethanol, 2-phenylethanol, benzylalcohol, 3-phenoxypropanol, and 3-phenylpropanol, whose structures are shown herein below.
• X is selected from C and O, and n is selected from 0, 1, 2, and 3,
• said compound is selected from the group consisting of phenoxyethanol, 2-phenylethanol, benzylalcohol, 3-phenoxypropanol, and 3-phenylpropanol, and
• R1 and R2 are selected from H, methyl, hydroxy, methoxy, or R1 together with R2 forms a 3,4-methylendioxy substituent, and
• R1 is H then R2 is selected from methyl, hydroxy, and methoxy, and
• R2 is hydroxy
• R1 is selected from H, hydroxy, and methoxy
• said benzaldehyde-derivative compound is selected from the group consisting of 4-methylbenzaldehyde, heliotropine, vanilline, 4-hydroxybenzaldehye, 3-hydroxybenzaldehyde, 4-methoxybenzaldehyde, 3-methoxybenzaldehyde, 2,4-dihydroxybenzaldehyde, 3-hydroxy-4-methoxybenzaldehyde, 3,5-dihydroxybenzaldehyde, and 4-hydroxy-2-methoxybenzaldehyde; and
• the at least one benzaldehyde-derivative compound according to formula II is present in a total concentration from 0.05 to 0.5% (w/w);
• composition is free from a bactericidally-, fungicidally-, sporicidally-effective or preservative concentration of compounds selected from the group consisting of:
• formaldehyde a formaldehyde donor compound including but not limited to diazolidinyl urea, imidazolidinyl urea, and DMDM Hydantoin;
• halogenated compound including but not limited to 2,4-dichlorobenzyl-alcohol, 4-chloro-3,5-dimethyl-phenol, 2-bromo-2-nitropropane-1,3-diol, and iodopropynyl butyl carbamate;
• a parabene compound including methyl-parabene, ethyl-parabene, propyl-parabene, butyl-parabene, isopropyl-parabene, and benzyl-parabene;
• a fungicide selected from quaternium-15 (CAS 51229-78-8), methyl-chloroisothiazolinone, and methylisothiazolinone.
• a personal care product composition as hereinabove described wherein the at least one compound a) is present in a concentration selected from 0.2 to 0.9%, 0.2 to 0.8%, and 0.3 to 0.6% (w/w);
• a personal care product composition as described above wherein the at least one compound b) is present in a concentration selected from 0.075 to 0.3%, and 0.1 to 0.2% (w/w);
• a personal care product composition as hereinabove described wherein the at least one compound a) is present in a concentration of 0.2 to 0.8% (w/w), and wherein the at least one compound b) is present in a concentration selected from 0.075 to 0.3%, and 0.1 to 0.2% (w/w);
• the at least one compound a) is present in a concentration of 0.3 to 0.6% (w/w), and wherein the at least one compound b) is present in a concentration selected from 0.075 to 0.3%, and 0.1 to 0.2% (w/w).
• compositions for personal care products applied to and left on the skin or scalp including creams, salves, lotions, and ointments for hand, face or body, perfumes, eau de Cologne, eau de toilet, deodorants, antiperspirants, and products applied to and rinsed off the skin or scalp including soaps, liquid soaps, shower gels, and shampoos.
• a personal care product comprising a personal care product composition as hereinabove described, in an application form selected from stick, roll-ons, spray, pump-spray, aerosol, soap bar, powder, solution, gel, cream, balm and lotion.
• the above lipid-comprising personal care product composition is provided in form of an emulsion.
• a preserved personal care product composition which is sufficiently bactericidal to have a reduction factor for Pseudomonas aeruginosa and Staphylococcus aureus of at least 1000 per 7 days, and is sufficiently sporicidal to have a reduction factor of 100 per 7 days for Aspergillus niger , by admixing an effective amount of the at least one compound a) and the at least one compound b) as hereinabove defined to a personal care product base, forming a personal care product composition with the proviso as hereinabove defined.
• a method of making a preserved personal care product by providing the personal care product composition formed as hereinabove described in a suitable personal care product application form that includes sticks, roll-ons, sprays, pump-sprays, aerosols, soap bars, powders, solutions, gels, creams, balms and lotions.
• Bases for personal care products are well known in the art and the resulting personal care product will usually have a pH of pH5 to pH9 (for example, slightly acidic for products applied to and left on the skin, slightly alkaline for soap products). It is also possible to employ an existing personal care product composition and simply add a) and b) in the concentrations hereinabove defined and mix thoroughly.
• concentration of compounds under a) and b) that is employed in a composition will depend upon the nature of the product and the preservative effect and length to be achieved, in particular the bactericidal, fungicidal and sporicidal activity.
• a useful concentration for the preservative compound a) is, for example, 0.1 to 1%, 0.2 to 0.8% or 0.3 to 0.6% (w/w).
• a useful concentration for the preservative enhancer compound b) is, for example, 0.05 to 5%, 0.075 to 0.3%, or 0.1 to 0.2% (w/w).
• the preservative a) and the preservative enhancer b) generally provide a sufficient bactericidal, fungicidal and sporicidal activity in a wide range of personal care product compositions.
• a sufficient bactericidal activity is attained when the reduction factor is 1000 per 7 days.
• a sufficient sporicidal activity is attained when the reduction factor is 100 per 7 days.
• a sufficient sporicidal activity is strongly indicative of a sufficient fungicidal activity.
• Fungicidal activity may easily be tested on yeast strains, using a mix of three Candida strains as described in example 4.
• a sufficient fungicidal activity is reached when the reduction factor is 100 per 7 days.
• the reduction factor is determined by growing a suitable test organism ( Aspergillus niger for fungi, Pseudomonas aeruginosa for gram-negative bacteria and Staphylococcus aureus for gram-positive bacteria) on a suitable culture medium on agar plates, harvesting and adding to a personal care product composition in a density of 3 ⁇ 10 5 organism/ml and counting the plated organisms in the probe and a negative control. The count of the negative control is divided by the count of the probe and thereby the reduction factor is determined (compare example 1).
• a suitable test organism Aspergillus niger for fungi, Pseudomonas aeruginosa for gram-negative bacteria and Staphylococcus aureus for gram-positive bacteria
• Preservative enhancers of particular interest are 4-hydroxybenzaldehyde and 3-hydroxybenzaldehyde, for their surprisingly good activity.
• the abovementioned compounds have only a low fragrance intensity. While highly fragrant compounds such as vanillin are restricted in their usefulness in personal care products depending on the fragrance note to be achieved (which may not be compatible), the abovementioned compounds can be combined with almost any personal care product without significantly altering the fragrance profile.
• Personal care product compositions are used to form a personal care product in an appropriate application form and packaging, as is well-known in the art.
• Personal care products and compositions to form them as described herein are used for the purpose of cleansing, conditioning, grooming, beautifying, promoting attractiveness, or otherwise enhancing or altering the appearance of the human body and are applied to the human skin or scalp.
• These products can, for example, take various forms of application, for example sticks, roll-ons, sprays, pump-sprays, aerosols, soap bars, powders, solutions, gels, creams, balms and lotions.
• Lipids are often included for example into washing formulations including liquid soaps or washing lotions to provide an oil replenishing effect.
• Preservative-enhancing compounds as hereinabove defined allow the formulation of preserved emulsions or formulations comprising lipids and/or detergents where the activity (the bactericidal, fungicidal and in particular the sporicidal effect) is not lost due to the presence of the lipid base and/or detergents or surfactants.
• personal care product compositions as described herein may also be combined with art-recognised quantities of other excipients commonly employed in these products; useful selections may be found in ⁇ CTFA Cosmetic Ingredient Handbook>>, J. M. Nikitakis (ed.), 1st ed., The Cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1988, which is hereby incorporated by reference.
• excipients may, for example, include colorants, fragrances, solvents, surfactants, colorants, opacifiers, buffers, antioxidants, vitamins, emulsifiers, UV absorbers, silicones and the like. All products can also be buffered to the desired pH using commonly-available excipients in a known manner.
• compositions, products, and related methods have been described above in connection with certain illustrative embodiments, it is to be understood that other similar embodiments may be used or modifications and additions may be made to the described embodiments for performing the same function. Further, all embodiments disclosed are not necessarily in the alternative, as various embodiments may be combined to provide the desired characteristics. Variations can be made by one having ordinary skill in the art without departing from the spirit and scope of the disclosure. Therefore, the compositions, products and methods should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the attached claims.
• Aspergillus niger ATCC 16404 spores are added to water to obtain a density of 3 ⁇ 10 5 spores/ml.
• the test strain is grown for 5 days on potato dextrose agar at room temperature.
• the spores are harvested with a solution containing 0.1% Tween 80, peptone 0.1% and NaCl 0.85% and the spore concentration is adjusted to the density indicated above.
• Test compounds are dissolved in dipropyleneglycol to a concentration of 20%.
• the reduction factor is determined as follows. Aliquots of the above prepared suspension of microorganisms (here: spore suspension prepared as described above) are plated on a suitable agar medium (see above) and the developing colonies are counted both for samples with test compound and for a negative probe (water). The count of the negative control is divided by the count of the test compound and thereby the reduction factor is determined. A negative control (water) accordingly has a reduction factor of 1 (no effect on the microorganism).
• Mefranal, and and 9-decenol show a significant sporicidal effect.
• a cosmetic cream (pH 5.5) for application to the human skin is formulated as follows (in % w/w):
• Glyceryl-monostearate 3 Glycerine 5 Xanthan gum 0.25 Stearic acid 7 Sweet almond oil 4 Glyceryl dilaurate 1 Cetyl-stearyl-alcohol 2 L-Arginine 0.5 Water add 100
• Glyceryl-monostearate, Sweet almond oil, Cetyl-stearyl-alcohol and Glyceryl dilaurate are melted at 80° C.
• Xanthan gum is dispersed into glycerine.
• Arginine is dissolved in water and heated to 75° C.
• the Xanthan gum-glycerin suspension is added to the heated water phase, the heated oil phase is added and the suspension is stirred at 300 rpm for 10 min whilst being cooled down slowly. Finally, a homogeneous emulsion is made with a high speed homogenizer at 5000 rpm.
• Test samples of cream contain different amounts of preservatives and/or preservative enhancer.
• the preservative and preservative enhancer is added to an aliquot of 10 g of the cream in 50 ml tubes to a concentration (w/w) of 0.1-0.5% as shown in the table below. After addition of the preservative/preservative enhancer, the cream is thoroughly mixed to achieve a homogeneous distribution.
• Table 2 shows the effects of test compounds combined with phenoxyethanol
• Mefranal and 9-decenol the compounds which have a sporicidal effect when used on their own in water at 0.1%), do not show an enhancing effect in the cosmetic cream in presence of phenoxyethanol, even at 0.2% concentration of Mefranal or 9-decenol.
• the sporidical effect in cream (prepared as described in example 2) is compared when using the test compounds alone or in combination with phenoxyethanol, benzyl alcohol or 2-Phenylethanol.
• Table 3 shows the sporicidal effect of test compounds in the presence of various preservatives (phenoxyethanol, benzyl alcohol or 2-Phenylethanol).
• Staphylococcus aureus (DSMZ 799) and Pseudomonas aeruginosa (ATCC 15442) are used.
• the strains are grown overnight in Mueller-Hinton broth and adjusted to a cell density of 1 ⁇ 10 8 cfu (colony forming units) per ml.
• the two bacterial strains are mixed in a ratio of 1:1 and 100 ⁇ l of this mixed inoculum is added to 10 ml aliquots of the cosmetic cream supplemented with test compounds as described in Example 2 in the concentration as indicated in the table below.
• the yeast strains are grown in Sabouraud liquid medium, washed and suspended in saline and adjusted to 5 ⁇ 10 7 cfu (colony forming units) per ml. The Inoculum of the three strains is then pooled in a ratio of 1:1:1. For determining the reduction factor by counting of the colonies formed, the samples inoculated with the yeast strains are spread plated on potato dextrose, incubated until colonies have formed and counted.
• test compound and preservative as indicated in Table 5.
• Table 5 indicates the concentrations in which test compound and preservative are tested in weight percent, and the results show the reduction factors (calculated as described herein-above) for a mix of bacteria (prepared as described in example 4) and A. niger after 24 hours or 7 days.
• test compound (4-hydroxybenzaldehyde) in presence of the preservative compound (phenoxyethanol).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Emergency Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Cosmetics (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=35841104

Family Applications (1)

Country Status (6)

Families Citing this family (19)

Citations (16)

• 2005
  • 2005-12-23 GB GBGB0526283.7A patent/GB0526283D0/en not_active Ceased
• 2006
  • 2006-12-18 US US12/097,958 patent/US9700499B2/en active Active
  • 2006-12-18 BR BRPI0620387A patent/BRPI0620387B1/pt active IP Right Grant
  • 2006-12-18 EP EP06828160.9A patent/EP1965752B1/en active Active
  • 2006-12-18 WO PCT/CH2006/000707 patent/WO2007071089A1/en active Application Filing
  • 2006-12-18 ES ES06828160.9T patent/ES2514472T3/es active Active

Patent Citations (16)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events